The impact factor of journal provides quantitative assessment tool for grading, evaluating, sorting and comparing journals of similar kind. It reflects the average number of citations to recent articles published in science and social science journals in a particular year or period, and is frequently used as a proxy for the relative importance of a journal within its field. It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information. The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Bone Marrow Transplantation (BMT) is a useful strategy for the treatment of leukemia, severe combined immune deficiency, enzyme deficiencies, autoimmune disease, and osteoporosis. Furthermore, Bone Marrow Transplantation plays an important role in the induction of immune tolerance in organ transplantation. Bone marrow is a spongy tissue, and is made up of Hematopietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), and various blood cells. HSCs differentiate into common myeloid- and lymphoid-precursor cells and then terminally differentiate into erythrocytes, monocytes, platelets, neutrophils, dendritic cells and other cells. MSCs can differentiate into not only mesoderm derived-cells such as adipocytes, osteoblasts, and osteoclasts, but also endodermand ectoderm-derived cells. Intra-Bone Marrow-BMT (IBM-BMT) has been proven to be the best strategy for allogeneic BMT as it results in the rapid recovery of hemopoietic function and the restoration of T cell functions since it can replace not only HSCs but also MSCs. It has been reported that IBM-BMT plays an important role in therapies for various diseases in animal models such as those of rheumatoid arthritis, Alzheimerâs disease and diabetes. Moreover, Intra-Bone Marrow-BMT has induced persistent donor-specific tolerance, and enables the use of reduced radiation doses as conditioning regimens in organ transplantation. Allogeneic Bone Marrow Transplantation is an effective immunotherapy for childhood leukemia. (Susumu Ikehara, Advances in Leukemia Treatment with Bone Marrow Transplantation)
Last date updated on January, 2021